A Translational Scientist’s Guide to World-Class Collaboration
Luis A. Diaz Jr, MD, is world renowned as a scientist and leader, but his greatest contribution to the world of cancer care might be as a collaborator and mentor.
Related Articles
Explore a treatment option for eligible adult patients with newly diagnosed AML that is FLT3-ITD+
Discuss efficacy and safety results from QuANTUM-First, which was a phase 3, randomized, double-blind, placebo-controlled trial exploring VANFLYTA in patients with newly diagnosed FLT3-ITD+ AML…
Frontline Amivantamab Plus Chemo Receives Positive EU CHMP Opinion for EGFR Exon 20 Insertion+ NSCLC
Frontline amivantamab with chemotherapy has been recommended for approval by the CHMP in EGFR exon 20 insertion+ non–small cell lung cancer.
Fox Chase Cancer Center Welcomes Dr Simon Sung
Fox Chase Cancer Center is pleased to announce the hiring of Simon Sung, MD, as an associate professor in the Department of Pathology.
CHMP Recommends Frontline Nivolumab Plus Chemo in Unresectable/Metastatic Urothelial Carcinoma
Frontline nivolumab plus chemotherapy has been recommended for approval in unresectable or metastatic urothelial carcinoma.
Fruquintinib Receives Positive EU CHMP Opinion for Previously Treated mCRC
CHMP has voiced its support for the approval of fruquintinib in previously treated metastatic colorectal cancer.
Navigating Personalized Approaches With Radiation Therapy for Early-Stage Breast Cancer
Robert W. Mutter, MD, discusses personalized treatment approaches with radiation and endocrine therapy with
DENALI Study Seeks to Prove Efficacy of Azenosertib in High-Grade Serous Ovarian Cancer
The phase 2 DENALI trial is investigating azenosertib in patients with high-grade serous ovarian cancer.
European Medicines Agency Grants Orphan Drug Designation to Annamycin in AML
The European Medicines Agency has granted orphan drug designation to annamycin for the treatment of patients with acute myeloid leukemia.
Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma
Paul G. Richardson, MD, speaks on the FDA’s decision to withdraw the approval of melflufen plus dexamethasone in multiple myeloma.
FDA Approves Lumisight and Lumicell DVS for Residual Breast Cancer Detection
The FDA has approved the optical imaging agent Lumisight and the Lumicell Direct Visualization System for use in fluorescence imaging in breast cancer.